Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2015 by Incyte Corporation
Information provided by (Responsible Party):
Incyte Corporation Identifier:
First received: June 19, 2013
Last updated: August 31, 2015
Last verified: August 2015

The study will be conducted in three parts. Part 1 is a dose escalation phase to determine the maximum tolerated dose (MTD) of INCB040093, a PI3Kδ inhibitor, or a tolerated, pharmacologically active dose; Part 2 will evaluate the combination of INCB040093 and INCB039110, a JAK1 inhibitor, to determine the MTD of the combination or a tolerated dose that produces substantial pharmacologic inhibition of both targets; Part 3 will further evaluate the chosen doses of INCB040093 alone and in combination with INCB039110 in subjects with relapsed/refractory B-cell malignancies.

Condition Intervention Phase
B-cell Malignancies
Drug: INCB040093
Drug: INCB040093 + INCB039110
Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Dose Escalation, Safety and Tolerability Study of INCB040093 in Subjects With Previously Treated B-Cell Malignancies

Further study details as provided by Incyte Corporation:

Primary Outcome Measures:
  • Safety and tolerability of INCB040093 as monotherapy and when given in combination with INCB039110 as determined by clinical laboratory assessments, physical exams, 12-lead ECG and summary of adverse events [ Time Frame: Measured every 3 weeks until progression. ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Preliminary efficacy as assessed by Overall Response Rate (ORR) as measured by published criteria for Hodgkin's/non-Hodgkin's lymphoma (Cheson et al 2007 and Owen et al 2013) and Chronic Lymphocytic Leukemia (CLL) (Cheson et el 2012) [ Time Frame: Every 12 weeks (4 cycles) until study withdrawal ] [ Designated as safety issue: No ]
  • Pharmacokinetic (PK) collections. [ Time Frame: Measured for each patient at Cycle 1 Day 1, Cycle 1 Day 8 and Cycle 1 Day 15 ] [ Designated as safety issue: No ]
    Plasma concentrations of each INCB040093 and INCB039110 will be used to estimate peak plasma concentration (Cmax) and area under the plasma concentration-time curve (AUC).

Estimated Enrollment: 120
Study Start Date: June 2013
Estimated Study Completion Date: May 2017
Estimated Primary Completion Date: December 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: INCB040093 Drug: INCB040093
Escalating doses starting at 100 mg every day (QD)
Drug: INCB040093
INCB040093 monotherapy - dose to be determined at completion of Phase I of the study
Experimental: INCB040093 in combination with INCB039110 Drug: INCB040093 + INCB039110
INCB040093 dose to be determined at completion of Part 1 of the study + INCB039110 at a starting dose of 400 mg, QD with escalations planned up to 600 mg QD.


Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

• Aged 18 years or older, with lymphoid malignancies of B-cell origin as follows:

o Indolent / aggressive B-cell (NHL) Non- Hodgkin's Lymphoma:

EXCLUDING: Burkitt lymphoma and precursor B-lymphoblastic leukemia/lymphoma

INCLUDING: any non-Hodgkin's B-cell malignancy such as CLL and rare non-Hodgkin's B-cell subtypes such as Hairy Cell Leukemia, Waldenstrom macroglobulinemia, Mantle cell lymphoma, transformed NHL histologies, etc.

o Hodgkin's lymphoma

  • Life expectancy of 12 weeks or longer.
  • Subject must have received ≥ 1 prior treatment regimen.
  • The subject must not be a candidate for potentially curative therapy, including stem cell transplant.

Exclusion Criteria:

  • Received an investigational study drug within 28 days or 5 half-lives (whichever is longer) prior to receiving the first dose of study drug.
  • Received any approved anticancer medications within 21 days or 5 half-lives (whichever is longer) prior to receiving their first dose of study drug (42 days for nitrosoureas) EXCEPT steroids at ≤ 10 mg prednisone daily (or equivalent).
  • Has any unresolved toxicity ≥ Grade 2 from previous anticancer therapy.
  • Has history of brain metastases or spinal cord compression, or lymphoma involving the central nervous system.
  • Has an Eastern Cooperative Oncology Group (ECOG) performance status of ≥ 3.
  • Received allogeneic hematopoietic stem cell transplant within the last 6 months, or has active graft versus host disease (GVHD) following allogeneic transplant, or is currently receiving immunosuppressive therapy following allogeneic transplant.
  • Received autologous hematopoietic stem cell transplant within the last 3 months.
  • Laboratory parameters not within the protocol-defined range.
  • Current or recent history (<30 days prior to screening and/or <45 days prior to dosing) of a clinically meaningful bacterial, fungal, parasitic or mycobacterial infection.
  • Current clinically active viral infection.
  • Known history of infection with the human immunodeficiency virus (HIV).
  • History of active hepatitis or positive serology for hepatitis.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01905813

Contact: Incyte Corporation Call Center 1.855.463.3463

United States, Alabama
Birmingham, Alabama, United States
United States, Florida
Jacksonville, Florida, United States
United States, Michigan
Ann Arbor, Michigan, United States
United States, New York
New York, New York, United States
Rochester, New York, United States
Sponsors and Collaborators
Incyte Corporation
Study Director: Matthew Spear, M.D. Incyte Corporation
  More Information

No publications provided

Responsible Party: Incyte Corporation Identifier: NCT01905813     History of Changes
Other Study ID Numbers: INCB 40093-102
Study First Received: June 19, 2013
Last Updated: August 31, 2015
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Neoplasms processed this record on October 08, 2015